Unit 1 · Topicals & penetration
Why most topical actives never reach the cell they are meant to act on
Topical therapy only works if the active survives the trip through the stratum corneum. By the end of this unit you should be able to explain why a well-chosen ingredient can still fail in a poorly formulated product, and what determines whether a molecule gets in at all.
Framing
Why topical therapy is not cosmetic in the superficial sense
In aesthetic medicine, evidence-based topical therapy serves three distinct roles: it prepares skin before procedural treatment, optimises and extends outcomes after it, and provides ongoing maintenance between visits.
The skincare industry produces a volume of product that far outpaces the evidence behind it, and many products market ingredients at concentrations too low to exert a biological effect. This module focuses on ingredients with a meaningful clinical evidence base.
- Correctors
- Actives that change something in the skin — retinoids, vitamin C, AHAs.
- Supporters
- Actives that maintain or restore the skin's own function — niacinamide, panthenol, vitamin E.
Both categories are clinically valuable, and the two most often work best together — a theme this module returns to directly in Unit 5.
Learn · Penetration pathways
How an ingredient actually crosses the stratum corneum
For a topical ingredient to be clinically active, it must penetrate the stratum corneum and reach its site of action. The skin's barrier function is precisely what makes this difficult.
The dominant pathway for most cosmetic actives is transcellular — directly through corneocytes — or intercellular — through the lipid matrix between cells. Follicular penetration is a secondary route that becomes more important for larger molecules.
The vehicle — serum, cream, oil, gel — that carries an active significantly influences how much of it reaches its target. A well-formulated serum with appropriate pH and penetration enhancers will outperform a poorly formulated product with a higher ingredient concentration on the label. This is why clinician-grade or prescription formulations frequently outperform comparable retail products — not always in ingredient, but in delivery system.
A client asks why her prescription-strength cream and her retail moisturiser, which list a similar active ingredient, produce such different results. Setting formulation quality aside for a moment, which route best describes how most cosmetic actives cross the stratum corneum?
Select an option to commit. The reasoning appears afterwards.
The dominant pathway for most cosmetic actives is transcellular — directly through corneocytes — or intercellular, through the lipid matrix between cells. Follicular penetration exists as a secondary route and becomes more relevant for larger molecules, but it is not the default explanation for why two similar-sounding products perform differently.
This is also why the question the client is really asking — why these two products differ — usually has more to do with formulation than with the pathway itself. Route of entry is necessary but not sufficient; what the vehicle does to support that route is the next layer of the answer.
Predict · What governs whether a molecule gets in
Molecular weight, lipophilicity and why pH is a delivery decision
Not every well-designed active reaches its target. A small number of molecular properties determine whether an ingredient can cross the lipid matrix at all — and one of the clearest examples in this module is vitamin C.
L-ascorbic acid is a small, water-soluble molecule. So why does a vitamin C serum need to be formulated at a low pH — around 2.5–3.5 — to penetrate the skin at all?
Hold your answer before you open this. The value is in having committed to a mechanism first.
Transcellular penetration is governed by four properties: molecular weight under 500 Da (smaller penetrates more readily); lipophilicity, with a log P between 1 and 3 as optimal — too hydrophilic and the molecule is rejected by the lipid matrix, too lipophilic and it cannot partition back into the aqueous intercellular environment; low ionisation at skin surface pH; and absence of excessive hydrogen bonding.
L-ascorbic acid at a higher, skin-neutral pH is ionised, and an ionised molecule is rejected by the lipid matrix regardless of its size. Formulating at pH 2.5–3.5 keeps the molecule in its non-ionised form, which is what allows it to partition into the stratum corneum. Molecular weight explains why it is small enough in principle; pH is what determines whether that potential is usable in practice.
A colleague plans to reformulate a 15% L-ascorbic acid serum to pH 5.5, reasoning that it will reduce stinging for sensitive-skin patients without meaningfully affecting efficacy. Based on what penetration requires, the most accurate response is:
Select an option to commit. The reasoning appears afterwards.
Effective penetration of L-ascorbic acid requires a formulation pH of 2.5–3.5. At this pH the molecule remains predominantly non-ionised, which allows it to partition into the lipid matrix. Raising the pH to 5.5 to reduce stinging would push more of the molecule into its ionised form, and an ionised molecule is rejected by the lipid matrix regardless of how small or water-soluble it otherwise is.
This is a genuine formulation trade-off, not a false concern — low-pH vitamin C is irritating for a meaningful proportion of patients. The clinically useful response is not to raise the pH, which sacrifices efficacy, but to move to a stable derivative formulated for sensitive skin, a decision this module returns to in Unit 4.
A patient bought a retail serum listing "10% vitamin C" as its headline ingredient, expecting results similar to the practitioner-dispensed serum she used after her last visit. Twelve weeks later she reports no visible change. Based on what determines topical efficacy beyond the ingredient list, the most useful next question is:
Select an option to commit. The reasoning appears afterwards.
The vehicle carrying an active significantly influences how much of it reaches its target. A well-formulated serum with appropriate pH and penetration enhancers will outperform a poorly formulated product with a higher ingredient concentration on the label. Concentration is one input; it is not the whole answer.
This is the practical reason clinician-grade or prescription formulations frequently outperform comparable retail products — not always because the ingredient itself differs, but because the delivery system does. It is a useful frame for setting patient expectations about retail alternatives to in-clinic recommendations.
Unit 1 summary
Clinical takeaways
- Topical therapy has three clinical roles. It prepares skin before procedures, optimises and extends outcomes after them, and provides maintenance between visits — it is not a cosmetic afterthought to a treatment plan.
- Penetration follows two dominant routes. Transcellular, through corneocytes, and intercellular, through the lipid matrix, with follicular penetration a secondary route that matters more for larger molecules.
- Four molecular properties gate transcellular delivery. Molecular weight under 500 Da, a log P between 1 and 3, low ionisation at skin surface pH, and limited hydrogen bonding. Vitamin C's low-pH formulation requirement follows directly from the ionisation rule.
- The vehicle is part of the active, not packaging around it. A well-formulated product at a lower concentration can outperform a poorly formulated one at a higher concentration — concentration on a label does not guarantee delivery.